Reliably Determining Reasonable Royalty Rates From Lump-Sum Licenses
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Written by: Susan E. Pratt, Ph.D. & Nathan D. Reeves
Before Lourie, Prost, and Reyna. Appeal from the United States District Court of the Western District of Texas.
Summary: License agreements containing a lump-sum payment “based on” a royalty rate may provide reliable evidence of a reasonable royalty rate for the licensed patent.
EcoFactor sued Google for patent infringement over Google’s smart thermostat products. At trial, the jury found Google infringed the patent and awarded EcoFactor damages. Google moved for a new trial on damages, arguing that the opinion of EcoFactor’s damages expert should have been excluded from trial for being speculative and unreliable. The district court denied the motion, and Google appealed.
The Federal Circuit affirmed the district court’s decision to deny Google’s motion for a new trial. On appeal, Google argued that the expert’s royalty rate was “plucked . . . out of nowhere” and that the damages testimony lacked comparability and apportionment. The Federal Circuit noted that the challenged expert’s testimony was based on three comparable licenses that contained lump sum payments “based on … a reasonable royalty calculation” at a particular rate and held that these licenses, along with corroborating evidence, adequately supported the rate. The Federal Circuit also held that the three licenses were economically comparable to the hypothetically negotiated agreement and properly apportioned because the expert accounted for the difference in scope between the licenses in analyzing the hypothetical negotiation. Consequently, the Federal Circuit concluded that the expert relied on sufficiently comparable licenses and that the expert’s opinion adequately apportioned the value of the patent. Thus, the damages opinion was admissible and the district court did not abuse its discretion when it denied Google’s motion for a new trial.
Editor: Sean Murray
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…